Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 224

Sort by

Sort Order Select

Journal Articles

Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia

Blood (2025) 146 (25): 3086–3097.

https://doi.org/10.1182/blood.2025030177

Published: 2025

Includes: Supplemental data

Journal Articles

Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panos Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Dr, Foteini Theodorakakou, Vasiliki Spiliopoulou, Irene Solia, Evangelos Eleutherakis-Papaiakovou, Giorgos Psarros, Efstathios Kastritis, Meletios A Dimopoulos

Blood blood.2025031629.

https://doi.org/10.1182/blood.2025031629

Published: 2025

Includes: Supplemental data

Journal Articles

Hematologist based management of ocular adverse events using the VRA tool in newly-diagnosed myeloma patients, ineligible for ASCT who received belantamab mafodotin plus lenalidomide/dexamethasone: Updated results from the randomized part 2 of bela-rd Study

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Eirini Solia, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Ilias Katsadouros, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Despina Fotiou, Helen Vassalou, Efstathios Kastritis, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 4038.

https://doi.org/10.1182/blood-2025-4038

Published: 2025

Journal Articles

Response-adapted randomization to Q2W vs Q4W isatuximab beyond cycle 6 in relapsed multiple myeloma: Results from a phase 2 Study of isa-pd in lenalidomide- and PI-exposed patients

Evangelos Terpos, Maria Gavriatopoulou, Vasiliki Lampropoulou, Emmanouil Spanoudakis, Eirini Katodrytou, Anastasia Sioni, Eleftheria Hatzimichael, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Eirini Solia, Nikolaos Kanellias, Helen Vassalou, Nikolaos Giannakoulas, Sosana Delimpasi, Maria Kotsopoulou, Efstathios Kastritis, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 4037.

https://doi.org/10.1182/blood-2025-4037

Published: 2025

Journal Articles

Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group

Evangelos Terpos, Efstathios Kastritis, Sosana Delimpasi, Maria Papathanasiou, Vasiliki Lampropoulou, Nikolaos Kanellias, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Evangelos Eleutherakis-Papaiakovou, Yagnik Vyas, Maria Kotsopoulou, Eirini Katodrytou, Maria Gavriatopoulou, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 4036.

https://doi.org/10.1182/blood-2025-4036

Published: 2025

Journal Articles

Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

Efstathios Kastritis, Maria Gavriatopoulou, Foteini Theodorakakou, Eirini Solia, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Stavroula Giannouli, Panagiotis Tsirigotis, Asimina Papanikolaou, Despina Fotiou, Konstantinos Giannakas, Erasmia Boutakoglou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 923.

https://doi.org/10.1182/blood-2025-923

Published: 2025

Journal Articles

Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens

Efstathios Kastritis, Eirini Solia, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Despina Fotiou, Stavroula Giannouli, Panagiotis Tsirigotis, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2228.

https://doi.org/10.1182/blood-2025-2228

Published: 2025

Journal Articles

Burden and characteristics of infections in patients treated with bispecific antibodies and the impact of immunoglobulin replacement

Efstathios Kastritis, Eirini Solia, Ilias Katsadouros, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2227.

https://doi.org/10.1182/blood-2025-2227

Published: 2025

Journal Articles

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival

Panagiotis Malandrakis, Ioannis Kostopoulos, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Sotirios Manganas, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Vasiliki Spiliopoulou, Magdalini Migkou, Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania Tsitsilonis, Meletios Dimopoulos, Evangelos Terpos

Blood (2025) 146 (Supplement 1): 2216.

https://doi.org/10.1182/blood-2025-2216

Published: 2025

Journal Articles

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Blood (2025) 146 (Supplement 1): 494.

https://doi.org/10.1182/blood-2025-494

Published: 2025

Journal Articles

The novel ims / IMWG high-risk multiple myeloma criteria may omit individuals with renal impairment and adverse disease prognosis

Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Eirini Solia, Evangelos Eleutherakis-Papaiakovou, Ilias Katsadouros, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Erasmia Boutakoglou, Konstantinos Giannakas, Evangelos Terpos, Meletios Dimopoulos, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 3986.

https://doi.org/10.1182/blood-2025-3986

Published: 2025

Journal Articles

Efficacy and safety of recombinant adjuvanted zoster vaccine in patients with monoclonal gammopathies: A prospective study

Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Eirini Solia, Ilias Katsadouros, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Terpos, Efstathios Kastritis, Meletios Dimopoulos, Maria Gavriatopoulou

Blood (2025) 146 (Supplement 1): 3985.

https://doi.org/10.1182/blood-2025-3985

Published: 2025

Journal Articles

Integrated transcriptomic and proteomic analysis of clonal plasma cells from patients with AL amyloidosis

Ourania Theologi, Ioannis Kollias, Kostantina Taouxi, Tina Bagratuni, Alexandra Papadimou, Katerina Chrisostomidou, Nefeli Mavrianou Koutsoukou, Agisilaos Papadopoulos, Christine-Ivy Liacos, Eleni Kalafati, Asimina Papanikolaou, Foteini Theodorakakou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos, Julie Courraud, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 3931.

https://doi.org/10.1182/blood-2025-3931

Published: 2025

Journal Articles

Nanopore sequencing-based profiling of circular RNAs in multiple myeloma uncovers circNFATC3 as a promising prognostic biomarker

Maria Papatsirou, Christos Kontos, Ioannis Ntanasis-Stathopoulos, Panagiotis Tsiakanikas, Christine-Ivy Liacos, Maria Gavriatopoulou, Efstathios Kastritis, Meletios Dimopoulos, Jerome Moreaux, Andreas Scorilas, Evangelos Terpos

Blood (2025) 146 (Supplement 1): 7452.

https://doi.org/10.1182/blood-2025-7452

Published: 2025

Journal Articles

Semaphorin 4D and interleukin 1beta-complement cascade axis are key drivers of disease progression in multiple myeloma

Ioannis Ntanasis-Stathopoulos, Panagiota-Efstathia Nikolaou, Charalampos Filippatos, Panagiotis Bakouros, Manousos Makridakis, Ioannis V. Kostopoulos, Christine-Ivy Liacos, Maria Frantzi, Panagiotis Malandrakis, Maria Gavriatopoulou, Antonia Vlahou, Efstathios Kastritis, Ourania Tsitsilonis, Meletios Dimopoulos, Evangelos Terpos

Blood (2025) 146 (Supplement 1): 3925.

https://doi.org/10.1182/blood-2025-3925

Published: 2025

Journal Articles

Impact of immunoglobulin supplementation on infection rates in myeloma patients receiving novel immunotherapies

Blood (2025) 146 (Supplement 1): 3999.

https://doi.org/10.1182/blood-2025-3999

Published: 2025

Journal Articles

Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapies

Foteini Theodorakakou, Zoey Kapsimali, Alexandra Papadimou, Katerina Chrisostomidou, Kostantina Taouxi, Ilias Katsadouros, Panagiotis Malandrakis, Magdalini Migkou, Eirini Solia, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Evangelos Eleutherakis Papaiakovou, Asimina Papanikolaou, Maria Gavriatopoulou, Evangelos Terpos, Eleni Pergantou, Meletios Dimopoulos, Ioannis Papassotiriou, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 2192.

https://doi.org/10.1182/blood-2025-2192

Published: 2025

Journal Articles

Characteristics and clinical course of younger Patients with early lesions in a contemporary cohort of 1240 patients: Low risk features and low risk of complications

Eirini Solia, Foteini Theodorakakou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Konstantinos Giannakas, Stavroula Giannouli, Panagiotis Tsirigotis, Asimina Papanikolaou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 2191.

https://doi.org/10.1182/blood-2025-2191

Published: 2025

Journal Articles

Management and long-term hematologic and neurologic outcomes of IgM-related neuropathy: A single center experience

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Sotirios Manganas, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Eirini Solia, Evangelos Eleutherakis-Papaiakovou, Ilias Katsadouros, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Terpos, Efstathios Kastritis, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2184.

https://doi.org/10.1182/blood-2025-2184

Published: 2025

Journal Articles

Novel criteria for evaluating early treatment response with whole body magnetic resonance imaging and prognostic implications in patients with newly diagnosed multiple myeloma

Ioannis Ntanasis-Stathopoulos, Vassilis Koutoulidis, Maria Gavriatopoulou, Maria Douka, Panagiotis Malandrakis, Charalampos Filippatos, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Ilias Katsadouros, Eirini Solia, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Lia-Angela Moulopoulos, Meletios Dimopoulos, Evangelos Terpos

Blood (2025) 146 (Supplement 1): 5765.

https://doi.org/10.1182/blood-2025-5765

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia

Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma

Hematologist based management of ocular adverse events using the VRA tool in newly-diagnosed myeloma patients, ineligible for ASCT who received belantamab mafodotin plus lenalidomide/dexamethasone: Updated results from the randomized part 2 of bela-rd Study

Response-adapted randomization to Q2W vs Q4W isatuximab beyond cycle 6 in relapsed multiple myeloma: Results from a phase 2 Study of isa-pd in lenalidomide- and PI-exposed patients

Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group

Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens

Burden and characteristics of infections in patients treated with bispecific antibodies and the impact of immunoglobulin replacement

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

The novel ims / IMWG high-risk multiple myeloma criteria may omit individuals with renal impairment and adverse disease prognosis

Efficacy and safety of recombinant adjuvanted zoster vaccine in patients with monoclonal gammopathies: A prospective study

Integrated transcriptomic and proteomic analysis of clonal plasma cells from patients with AL amyloidosis

Nanopore sequencing-based profiling of circular RNAs in multiple myeloma uncovers circNFATC3 as a promising prognostic biomarker

Semaphorin 4D and interleukin 1beta-complement cascade axis are key drivers of disease progression in multiple myeloma

Impact of immunoglobulin supplementation on infection rates in myeloma patients receiving novel immunotherapies

Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapies

Characteristics and clinical course of younger Patients with early lesions in a contemporary cohort of 1240 patients: Low risk features and low risk of complications

Management and long-term hematologic and neurologic outcomes of IgM-related neuropathy: A single center experience

Novel criteria for evaluating early treatment response with whole body magnetic resonance imaging and prognostic implications in patients with newly diagnosed multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only